Dividends & Buybacks ·
AIM ImmunoTech Inc. held a Special Meeting of Stockholders on July 15, 2026, where shareholders approved seven proposals
AIMIAIM ImmunoTech Inc.
AIM ImmunoTech Inc. held a Special Meeting of Stockholders on July 15, 2026, where shareholders approved seven proposals. Key approvals include permission to issue more than 19.99% of outstanding common stock to comply with NYSE American rules regarding the exercise of Class H, Class I, and Class J warrants, as well as the conversion of two specific promissory notes dated February 16, 2024, and November 18, 2025. Additionally, stockholders approved a series of alternate amendments to the Certificate of Incorporation allowing the Board of Directors to implement a reverse stock split of up to a 1-for-25 ratio. The meeting also approved the ability to adjourn the meeting if necessary for further proxy solicitation. AIM ImmunoTech Inc. is a biotechnology company focused on developing cancer immunotherapies.